ResearchAndMarkets.com adds gene therapy collaboration and licensing deals 2016-2026 report

ResearchAndMarkets.com has added the "Gene Therapy Collaboration and Licensing Deals 2016-2026" report to its offering, introducing a transaction-focused study of more than 850 gene therapy partnerships across the past decade. The report is positioned as a benchmark for how companies structure, negotiate and execute collaboration and licensing agreements in a field shaped by complex development timelines, manufacturing demands, regulatory hurdles and long-term value expectations. The publication says it provides analysis of upfront payments, milestones and royalty structures where disclosed, along with a searchable directory organized by company, therapy type and development stage. It also offers access to SEC-filed agreements and other source documents so users can review how rights are allocated, which responsibilities are assigned across development and commercialization, what payment triggers apply and what contractual protections are used in practice. ResearchAndMarkets.com presents the report as a practical tool for business development and strategy teams seeking to benchmark comparable transactions, define market parameters for valuation and deal structuring, prepare for negotiations and evaluate licensing, co-development and platform partnerships. The company says the report also analyzes broader deal trends, key transactions and active dealmakers in gene therapy.